Bisphosphonates for steroid induced osteoporosis
Editorial Group: Cochrane Musculoskeletal Group
Published Online: 25 JAN 1999
Assessed as up-to-date: 16 NOV 1998
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Homik J, Cranney A, Shea B, Tugwell P, Wells GA, Adachi J, Suarez-Almazor ME. Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001347. DOI: 10.1002/14651858.CD001347.
- Publication Status: Edited (no change to conclusions)
- Published Online: 25 JAN 1999
Corticosteroids are widely used in inflammatory conditions as an immunosuppressive agent. Diseases treated with corticosteroids include connective tissue diseases, asthma, inflammatory bowel disease and organ transplantation. Bone loss is a serious side effect of this therapy. Several studies have examined the use of bisphosphonates as a treatment for corticosteroid-induced osteoporosis and have reported varying magnitudes of effect. The best estimate of the magnitude of efficacy regarding bisphosphonate prevention of corticosteroid-induced bone loss is needed, before their use is advocated.
To assess the effects of bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis.
We searched the Cochrane Musculoskeletal Group trials register, MEDLINE up to 1997 and EMBASE 1988-1997), and selected hand searching of reference lists was conducted. Hand searching of scientific abstracts from relevant meetings for the last five years was also done. An electronic search in Current Contents was done for the last six months. The Cochrane Controlled Trials Register (CCTR) will be searched for future updates.
All languages were included in the search. For practical reasons only those in English were included, but all languages will be retrieved and translated for future updates.
All controlled clinical trials (CCTs) dealing with prevention or treatment of corticosteroid-induced osteoporosis with bisphosphonates of any type and reporting the outcomes of interest were assessed. Trials had to involve adults only, and subjects had to be taking a mean steroid dose of 7.5 mg/day or more.
Data collection and analysis
All data extraction was performed by two independent reviewers. Outcomes of interest included change in bone mineral density (BMD) at the lumbar spine and femoral neck at six and 12 months. If present, data on number of new fractures and withdrawals due to adverse effects were also extracted. All data extraction was performed by two independent reviewers.
Both continuous and dichotomous data were analyzed using fixed effects models. When significant heterogeneity was present, a random effects model was used.
A total of 13 trials, including 842 patients are included in this meta-analysis. Results are reported as a weighted mean difference of the percent change in BMD between the treatment and placebo groups, with trials being weighted by the inverse of their variance. The 95% confidence intervals (95% CI) are presented. At the lumbar spine, the weighted mean difference of BMD between the treatment and placebo groups was 4.3% (95% CI 2.7, 5.9). At the femoral neck, the weighted mean difference was 2.1% (95%CI 0.01, 3.8). Although there was a 24% reduction in odds of spinal fractures [OR 0.76 (95%CI 0.37, 1.53)], this result was not statistically significant.
Bisphosphonates are effective at preventing and treating corticosteroid-induced bone loss at the lumbar spine and femoral neck. Efficacy regarding fracture prevention cannot be concluded from this analysis, although bone density changes are correlated with fracture risk.
Plain language summary
Bisphosphonates for treating osteoporosis caused by the use of steroids
Corticosteroids are widely used to treat inflammation. Bone loss (osteoporosis) is a serious side effect of this therapy. We reviewed a total of 13 trials which included 842 patients. We found that the bone mineral density of the lumbar spine of patients taking bisphosphonate therapy improved 4.3% more than patients who had no treatment. At the femoral neck (top of the thigh bone), the bone mineral density improved 2.1% more in the treatment group. There was no difference in the number of spinal fractures between the the two groups. We found that bisphosphonates are effective at preventing and treating corticosteroid-induced bone loss at the lumbar spine and femoral neck. We do not have enough evidence to say whether or not bisphosphonates prevent fractures.
搜尋包括 Cochrane Musculoskeletal Group trials register, MEDLINE到1997 and EMBASE 1988 – 1997)，CCTR，同時手動搜尋回顧文章之參考文獻及近5年研討會論文，及近6個月Current Contents。
13個研究包含842例病患於分析中。結果為治療組與安慰劑組骨密度改變百分比之加權平均差異(WMD)，並以變異數倒數為加權。在腰椎，骨密度改變百分比之加權平均差異為4.3% (95% CI 2.7, 5.9)。在股骨頸之加權平均差異為2.1% (95% CI 0.01, 3.8)。雖然脊椎骨折勝算減少24% ，但無統計差異 OR 0.76 (95% CI 0.37, 1.53)]。
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。